Get started
Author

Dong-Hoon Yeom

Observed names: D. Yeom, Dong-Hoon Yoem, Donghoon Yeom
ORCID: 0009-0004-1974-0081
Observed ORCID: 0009-0004-1974-0081
OpenAlex ID: A5002426660
Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis
2016 · Dongheon Lee, Dongin Kim, et al. · mAbs · 46
PDF
ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models
2020 · Dong-Hoon Yeom, Yo-Seob Lee, et al. · International Journal of Molecular Sciences · 39
PDF
Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer
2020 · Da-Hyun Kim, Seul Lee, et al. · BMB Reports · 21
PDF
Weakening of the repressive YY-1 site on the thrombospondin-1 promoter via c-Jun/YY-1 interaction
2004 · Jung-Hoon Kang, Seo-Yoon Chang, et al. · Experimental & Molecular Medicine · 12
PDF
544P A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation
2021 · E. Lee, H. Chung, et al. · Annals of Oncology · 3
PDF
Differential regulation of thrombospondin-1 expression and antiangiogenesis of ECV304 cells by trichostatin A and helixor A
2007 · Susie Hong, Seo-Yoon Chang, et al. · Anti-Cancer Drugs · 3
Abstract 6354: The HER2/4-1BB bispecific antibody, YH32367 (ABL105) demonstrates optimal efficacy and safety for HER2-expressing tumors and exhibits synergistic efficacy when combined with anti-PD-L1
2024 · Eunjung Lee, Young Bong Park, et al. · Cancer Research · 2
Abstract 6524: A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) shows potent anti-tumor effect through tumor-directed T cell activation
2020 · Moo Young Song, Eun-Jung Lee, et al. · Cancer Research · 2
ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al. · Molecular Cancer Therapeutics · 1
Abstract 1139: A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exhibits the optimal efficacy and superior safety profile through tumor-directed 4-1BB agonism
2022 · Eunjung Lee, Hyejin Chung, et al. · Cancer Research · 1
Data from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 3 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S5 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Table S3 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Table S2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 5 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Table S4 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S6 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 4 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S16 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S14 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure S2 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 1 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Figure 6 from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window
2026 · Bora Lee, Hyeon Ji Park, et al.
Works count: 41
Citation count: 130
H-index: 4
I10-index: 4
Year
Topic
Type